Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03246724 · ClinicalTrials.gov registry record · Phase 4
Oral Versus Intravenous Sedation for Ocular Procedures
A Phase 4 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 327
- Enrollment target
NCT03246724 is a Phase 4 study that has completed, run by Boston Medical Center. The registered enrollment target is 327 participants.
The verdict
NCT03246724, a Phase 4 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 327 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate patient satisfaction after eye surgery when given a capsule compared to an intravenous (IV) dose of sedation (calming medication). Each subject will be given a capsule and an IV in the hospital before their procedure starts, however they will not know which one is the sedation route. Each subject will have their planned surgical procedure as previously discussed with their doctor. After the procedure is completed, the doctors will complete satisfaction surveys. The subject will also complete a satisfaction survey during their regularly scheduled visit the day after surgery. Once the subject completes this survey, their study participation will be complete. The hypothesis is that there will be no difference in patient satisfaction when given a capsule in comparison to IV sedation. If the results of the study support this hypothesis, a capsule could be used in place of IV sedation. By using a capsule for ocular procedures, both patients and the medical practice would benefit: patient would be able to eat before their procedure, patient costs would be decreased, hospital costs would be reduced, and some of these procedures would be given the option to move to a procedure room (freeing up operating room time for other departments).
Interventions
- DRUG Midazolam
- DRUG Triazolam
- DRUG Microcrystalline Cellulose
- DRUG Sodium chloride 0.9%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2019-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03246724
The ClinicalTrials.gov registry entry for NCT03246724 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.
NCT03246724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03246724 about?
NCT03246724 is a clinical study titled "Oral Versus Intravenous Sedation for Ocular Procedures". The purpose of this study is to evaluate patient satisfaction after eye surgery when given a capsule compared to an intravenous (IV) dose of sedation (calming medication). Each subject will be given a capsule and an IV in the hospital before their procedure starts, however they will not know which ...
What is the current status of trial NCT03246724?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 327 participants. The study started on 2017-10-16. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT03246724?
The interventions under investigation include: Midazolam (DRUG), Triazolam (DRUG), Microcrystalline Cellulose (DRUG), Sodium chloride 0.9% (DRUG).
Who is sponsoring clinical trial NCT03246724?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.